Toll like receptors promote high glucose-induced vascular endothelial cell dysfunction by regulating neutrophil extracellular traps formation

doi:10.21203/rs.3.rs-5048942/v1

Download PDF

Research Article

Toll like receptors promote high glucose-induced vascular endothelial cell dysfunction by regulating neutrophil extracellular traps formation

https://doi.org/10.21203/rs.3.rs-5048942/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Diabetic retinopathy (DR) is a major cause of blindness globally. Neutrophils and neutrophil extracellular traps (NETs) are believed to play a role in the development of DR. However, the specific contribution of NETs to hyperglycemia-induced vascular endothelial cell dysfunction remains unclear. In this study, we cocultured high glucose-activated neutrophils (HGNs) with human umbilical vein endothelial cells (HUVECs) to investigate the role of NETs in high glucose-induced HUVEC dysfunction. Our findings indicate that high glucose levels promote NETs formation, which can be inhibited by a toll-like receptor (TLR) 2 antagonist and a TLR4 antagonist. It was observed that reactive oxygen species production plays a role in TLR2- but not TLR4-mediated NETs formation. Additionally, HGNs were found to promote HUVEC proliferation through phagocytosis rather than NETs. We also discovered that NETs contribute to high glucose-induced HUVEC dysfunction by enhancing neutrophil-HUVEC adhesion, inhibiting HUVEC migration, and compromising the barrier function of the cells by reducing zonula occludens-1 expression. This dysfunction could be partially mitigated by TLR2 and TLR4 antagonists. In conclusion, high glucose stimulates NETs formation, leading to vascular endothelial cell damage, and TLRs may facilitate high glucose-induced endothelial dysfunction by modulating NETs formation.

neutrophils

neutrophils extracellular nets

diabetic retinopathy

HUVEC

permeability

toll-like receptor

Diabetes mellitus (DM) is a chronic metabolic disease, and the prevalence of DM has been steadily increasing in China and globally, with a trend toward a younger age of onset[1]. It is estimated that the number of patients with DM worldwide will reach 700 million by 2045[2]. Diabetic retinopathy (DR) is one of the most severe microvascular complications of DM; it can lead to vision loss due to hemorrhage, exudates, edema, and retinal detachment[3, 4]. As the incidence of DM is rising and patients with DM are surviving longer, an increasing number of people are experiencing DR and related vision loss[5]. Nowadays, laser photocoagulation, vitrectomy, intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs or steroids are used to treat DR[6, 7]. However, laser photocoagulation and vitrectomy result in unavoidable damage, the curative effect of anti-VEGF drugs and steroids is temporary and intravitreal steroid injections are associated with complications, such as an increased risk of developing cataracts and glaucoma[8]. Additionally, stem cell therapy and photobiomodulation are emerging treatments for DR[9, 10]. However, the former is costly and time-consuming, while the latter still requires extensive clinical validation. Thus, there are ongoing efforts to identify the molecular mechanisms involved in the pathogenesis of DR and develop better treatment modalities for this condition.

Chronic inflammation induced by chronic hyperglycemia is considered a significant contributing factor of DR[11, 12]. Several inflammatory cell types and molecules have been implicated in the pathogenesis of DR; they have been shown to cause retinal vascular cell dysfunction, retinal hemorrhage, macular edema, retinal neovascularization, and retinal detachment in DR patients[13, 14]. Moreover, it has been demonstrated that the development of DR in animal models can be prevented by applying anti-inflammatory therapies[15].

Neutrophils are important immune and inflammatory cells in the human body, and they have been implicated in the pathogenesis of DR. More specifically, peripheral blood neutrophil levels were found to be positively associated with disease severity in both DM and DR[16]. Neutrophil extracellular traps (NETs) is another effector mechanism of neutrophil, which were first proposed by Brinkmann et al. in 2004[17]. It is demonstrated that NETs not only participate in the body’s defense mechanisms but also serve as a key pathogenic factor in a range of non-infectious inflammatory diseases, including autoimmune disorders, self-inflammatory conditions, and metabolic diseases, such as DM[12]. High glucose has been reported to increase the formation of NETs both in vivo and in vitro[18]. Furthermore, DR patients had higher levels of NET components in the peripheral blood than diabetic patients without DR[19]. Moreover, NETs have been shown to trigger proinflammatory immune responses and induce endothelial dysfunction, which subsequently leads to increased endothelial permeability, endothelial barrier collapse, impaired wound repair, and angiogenic dysfunction in several non-infectious inflammatory diseases[20–22]. However, the role that NETs play in high glucose-induced endothelial cell dysfunction and the underlying mechanism are not clear.

Toll-like receptors (TLRs) are fundamental pattern recognition receptors that help cells recognize microbial structures and mediate subsequent inflammatory responses[23, 24]. As important components of neutrophil-related inflammatory processes, TLRs have been reported to participate in the formation of NETs after stimulation with Trypanosoma brucei lipophosphoglycan and gut-derived lipopolysaccharide[25, 26]. Our previous research also confirmed that TLRs participate in regulating NETs formation induced by Staphylococcus aureus[27]. Furthermore, TLRs have been found to be involved in the pathogenesis of DM and DR[28]. Zhu et al. reported that TLR4 expression was elevated in the peripheral blood of patients with type 2 DM[29], and Kim et al. reported that TLR2 is associated with the death of pancreatic β cells[30]. Moreover, it has also been demonstrated that TLR4 gene polymorphism is associated with the elevated incidence of DR and that TLR4 deletion alleviates the development of DR in mice[31, 32]. These findings suggest that TLRs may play a crucial regulatory role in the development of DR by regulating NETs formation under conditions of persistent high blood glucose. However, the role that TLRs play in high glucose-induced NETs formation and vascular endothelial cell dysfunction remains unknown.

Therefore, we conducted this study to elucidate the role that NETs play in high glucose-stimulated vascular endothelial cell dysfunction. We also examined the effect of TLR2 and TLR4 on high glucose-stimulated NETs formation and subsequent vascular endothelial cell dysfunction.

2.1. Reagents

Peripheral blood neutrophil isolation kit was purchased from TBD sciences. 4% paraformaldehyde (PFA), Triton X-100, horseradish peroxidase (HRP) were purchased from Solarbio (Beijing, China). DNase I, cytochalasin D, dichlorofluorescein diacetate (DCF-DA), bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO, USA). TMB Chromogen Solution, Stop Solution for TMB Substrate were purchased from Beyotime (Shanghai, China). TLRs antagonists were purchased from InvivoGen (San Diego, CA, USA). Anti-histone H3 antibody, horseradish peroxidase (HRP), and secondary antibodies coupled to AF488 or AF555 were purchased from Santa Cruz Biotechnology (CA, USA). Anti-zonula occludens-1 (ZO-1) tight junction protein antibody and anti-myeloperoxidase (MPO) antibody were purchased from Abcam (Cambridge, UK). Optimal cutting temperature compound (OCT) was purchased from Sakura (LA, USA), Diphenyleneiodonium chloride (DPI), were purchased from MCE(NJ, USA), SYTOX Green, Dulbecco's Modified Eagle Medium/Nutrient Mixture F12 (DMEM/F12), Roswell Park Memorial Institute (RPMI) 1640, micro-plates were purchased from ThermoFisher Scientific (Basingstoke, UK). Cell proliferation reagent water-soluble tetrazolium salt-1 (WST-1) was purchased from Roche (Basal, Switzerland).

2.2. Human Primary Neutrophils Isolation

This study was approved by the Ethics Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University. All procedures for sample collection complied with the principles of the Helsinki Declaration on Human Subjects. All human subjects taking part in the present study signed the informed consent. Neutrophils were isolated from peripheral blood of healthy volunteers using peripheral blood neutrophil isolation kits. The neutrophil content was more than 96% as determined by Wright-Giemsa staining, and the cell viability was 98% as determined by Trypan blue staining. Isolated neutrophils were cultured in RPMI-1640 medium with 2% bovine serum albumin.

2.3. Neutrophils Stimulation

Neutrophils (1x10⁶ cells/well in 1mL) placed in a humidified incubator at 37°C with 5% CO₂ were treated with different concentrations of glucose for 2 hours. In some experiments, neutrophils were pretreated with TLR2 antagonist (1 µg/mL), TLR4 antagonist (1 µg/mL), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor (diphenyleneiodonium, DPI,10 uM), or vehicle(controls) for 1hour.

2.4. Immunofluorescence for NETs Formation

After stimulation, neutrophils were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, blocked with 10% goat serum, incubated with primary antibodies against Histone H3 and MPO overnight at 4℃, and followed by secondary antibodies incubation for 1 hour at room temperature. Meanwhile, DNA was stained with 4',6-diamidino-2-phenylindole (DAPI). Subsequently, specimens were fixed and analyzed under an inverted fluorescence microscope (Leica DMi8).

NETs formation was also detected by using SYTOX Green, which is a commonly used membrane-impermeable DNA-binding dye. After stimulation, SYTOX Green (5 µM) was added to the medium, and the NETs structure were observed and imaged by using an inverted fluorescence microscope 5 minutes later.

2.5. ROS Production

Neutrophils were incubated with 10 µM DCF-DA in serum-free RPMI-1640 at 37°C for 20 minutes, followed by washing with phosphate-buffered saline (PBS) for three times and transferring to a 96-well plate (1×10⁶ cells per well in 100 µl). Subsequently, the cells were pretreated with TLR2 antagonist or TLR4 antagonists for 1 hour and then stimulated with vehicle or 35 mM glucose. After 2 hours stimulation, the fluorescence signal of DCF-DA was measured by using SpectraMax M3 Multi-Mode Microplate Reader with 480 nm excitation wavelength and 520 nm emission wavelength.

2.6. HUVEC stimulation

HUVEC (purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd) were incubated in DMEM/F12 supplemented with 10% bovine serum albumin. To investigate the effect of high glucose-activated neutrophils (HGNs) on HUVEC and the underlying mechanism, HUVEC were co-cultured with HGNs pretreated with TLR2 antagonist, TLR4 antagonist or vehicle. In order to distinguish the effect of NETs form neutrophil phagocytosis, DNase I (100 U/mL) was used to degrade the structure of NETs and Cytochalasin D (100 µg/mL) was used to inhibiting neutrophil phagocytosis.

2.7. HUVEC Proliferation Assessment

HUVEC were cultured overnight in a 96-well plate according to a concentration gradient. Then the HUVEC were co-cultured with vehicle, HGNs, HGNs with DNase I or HGNs with Cytochalasin D for 24 hours. Subsequently, the cells were incubated with 10 µl WST-1 at 37 ℃ for another 4 hours and the absorbance at 450 nm and 690 nm were measured by using SpectraMax M3 Multi-Mode Microplate Reader to quantify the HUVEC proliferation.

2.8. Neutrophil-HUVEC Adhesion Assay

HUVEC with green fluorescent protein (HUVEC-GFP) (5.0×10⁴ cells/well) were incubated overnight in 12-well plates, and the neutrophils were labeled with Hoechst 33342(4×10⁶ cells/mL). Subsequently, the monolayer HUVEC were co-cultured in DMEM/F12 with neutrophil, HGNs, HGNs with DNase I, HGNs with Cytochalasin D, HGNs with TLR2 antagonist or HGNs with TLR4 antagonist for 2 hours. After that, non-adherent neutrophils were gently removed by washing with DMEM/F12 and adherent neutrophils were imaged by an inverted fluorescence microscope (Leica DMi8) and analyzed by Image J (National Institutes of Health, the USA). The ratio of the number of neutrophils to HUVEC was calculated as the adhesion rate.

2.9. HUVEC Migration Assay

HUVEC-GFP(5×10⁴ cells/well) were cultured in a 12-well plate overnight to reach confluence. The wounding was created by drawing a line with a 200uL pipette tip, and the cells debris was removed by gently wash twice with PBS. Then the HUVECs were incubated with vehicle, HGNs, HGNs with DNase I, HGNs with Cytochalasin D, HGNs with TLR2 antagonist or HGNs with TLR4 antagonist. Twenty-four hours after incubation, the wound size was observed by taking images with an invert fluorescence microscope (Leica DMi8) and analyzed by Image J (National Institutes of Health, the USA). HUVEC migration was evaluated by calculating the wound closure percentage on the scratch.

2.10. HUVEC Permeability Assay

HUVEC cultured on polycarbonate cell culture inserts with pores of 4.0 µm were allowed to reach confluence overnight. Then HUVEC were treated with vehicle, HGNs, HGNs with DNase I, HGNs with Cytochalasin D, HGNs with TLR2 antagonist or HGNs with TLR4 antagonist overnight, followed by the addition of 100 ng/mL HRP. After incubating at 37°C for 30 minutes, 50 µL medium from the lower chamber was collected and incubated with the TMB chromogen solution for 3 minutes. The absorbance values of HRP were read by a microplate reader at a wavelength of 450 nm, which indirectly reflected the permeability of HUVEC.

Furthermore, the filter membrane material with attached HUVECs was cut from the chamber. After washing with PBS, cells were fixed with 4% PFA for 15 minutes, followed by incubation in Triton X-100 for 5 minutes. Then, serum blocking was carried out for 30 minutes and ZO-1 antibody was added for overnight incubation at 4°C. After washing with PBS, cells were incubated with secondary antibodies for 1 hour at room temperature. Following PBS washing and DAPI counterstaining, ZO-1 protein was observed under a florescence microscope.

2.11. Statistical Analysis

Statistical analysis was performed using GraphPad Prism 9.0 (GraphPad Software, the USA). Data are presented as mean ± standard error (SE). We used Student's t-test to compare the values between two group and analysis of variance (ANOVA) followed by Bonferroni's post hoc test to compare among multiple groups. Levels of significance was set at 0.05.

3.1. High glucose level promoted NETs formation

The NETs formation that occurred during incubation with different concentrations of glucose (11, 15, 25, or 35 mM) for 120 min is shown in Fig. 1a. NETs formation was validated by immunofluorescence staining of MPO (red) and histones (green) with respective antibodies, and of DNA (blue) with DAPI. The NETs formation that occurred during incubation with 35 mM glucose was further confirmed by SYTOX Green staining (Fig. 1b), which could be degraded by DNase I. As the NETs present after incubation with 11, 15, and 25 mM glucose were little, 35 mM glucose and a stimulation time of 120 min were used for subsequent experiments.

3.2. High glucose-induced NETs formation was inhibited by a TLR2 antagonist and a TLR4 antagonist

To validate the impact of TLRs on NETs production under high glucose conditions, neutrophils were pretreated with a vehicle, TLR2 antagonist, or TLR4 antagonist for 1 h. NETs formation was observed using SYTOX Green staining under a fluorescence microscope after stimulating neutrophils with or without 35 mM glucose (Fig. 2a). As expected, both the TLR2 and TLR4 antagonists reduced the high glucose-induced NETs formation (Fig. 2b).

3.3. ROS production was involved in TLR2- but not TLR4-regulated NETs formation

The formation of NETs can be either an ROS-dependent or ROS-independent process; thus, we used a DCF-DA fluorescence assay to determine whether high glucose-stimulated NETs formation is ROS dependent. We also assessed the impact of an NADPH oxidase inhibitor (diphenyleneiodonium [DPI]) on high glucose-induced NETs formation. As expected, an oxidative burst was observed in neutrophils upon exposure to a high glucose concentration (Fig. 3a). The NETs formation that was induced by high glucose was reduced by pretreatment with DPI (Fig. 3b, 3c), which indicated that the process was ROS dependent. We also explored whether TLRs regulate high glucose-stimulated NETs formation by modulating ROS production. We found that the TLR2 antagonist reduced the high glucose-induced ROS production and that the TLR4 antagonist had no effect (Fig. 3d). These results indicated that ROS production is involved in TLR2- but not TLR4-regulated NETs formation.

3.4. HGNs promoted HUVEC proliferation via phagocytosis and not via NETs

A WST-1 assay was used to assess HUVEC proliferation. To distinguish the effects of NETs from those of neutrophil phagocytosis, cytochalasin D was used to inhibit neutrophil phagocytosis and DNase I was used to degrade NETs. When HUVECs are at low concentrations, high glucose-activated neutrophils (HGNs) promoted the proliferation of HUVECs, and this proliferative effect could be significantly inhibited by cytochalasin D (Fig. 4). However, DNase I neither enhanced nor inhibited the HGN-promoted HUVEC proliferation. These results indicated that HGNs promoted HUVEC proliferation, possibly via neutrophil phagocytosis but not via NETs formation.

3.5. NETs were involved in high glucose-induced neutrophil–HUVEC adhesion, which could be inhibited by a TLR2 antagonist and a TLR4 antagonist

The results of the adhesion assay showed that high glucose promoted neutrophil–HUVEC adhesion (Fig. 5). DNase I, which degrades and thus eliminates NETs, was found to significantly inhibit neutrophil–HUVEC adhesion, while cytochalasin D had no effect. The TLR2 and TLR4 antagonists both reduced the high glucose-induced neutrophil–HUVEC adhesion. These results suggest that NETs promote high glucose-induced neutrophil–HUVEC adhesion and that this process can be modulated by TLR2 and TLR4.

3.6. HGNs inhibited HUVEC migration by generating NETs, and the migration could be partially rescued by a TLR2 antagonist and a TLR4 antagonist

As shown in Fig. 6, HUVEC migration was determined using a wound-healing assay. The results showed that HGNs significantly inhibited HUVEC migration. DNase I significantly alleviated this inhibition of HUVEC migration, while cytochalasin D had no effect. These results indicated that HGNs may inhibit HUVEC migration through the formation of NETs. Furthermore, the TLR2 and TLR4 antagonists could attenuate the HGN-inhibited HUVEC migration, which suggested that TLR2 and TLR4 may participate in HGN-induced HUVEC migration inhibition by regulating NETs formation.

3.7. HGNs disrupted the barrier function of HUVECs through NETs formation, and TLRs may have modulated this process

We evaluated the leakage of horseradish peroxidase (HRP) to assess the barrier function of the HUVECs. The results showed that HGNs significantly increased HUVEC permeability (Fig. 7). DNase I significantly reduced the HGN-induced HUVEC permeability, while cytochalasin D had no significant impact. The TLR2 and TLR4 antagonists significantly reduced the HGN-induced HUVEC permeability. When the HUVECs were subjected to immunofluorescence staining, zonula occludens-1 (ZO-1) was observed in the HUVECs. The expression of ZO-1 was significantly lower in cells exposed to HGNs. DNase I rescued the HGN-reduced ZO-1 expression, while cytochalasin D had no effect. It was also observed that the TLR2 and TLR4 antagonists attenuated the HGN-reduced ZO-1 expression in the HUVECs. These results indicated that NETs are involved in HGN-mediated HUVEC barrier function damage and that TLR2 and TLR4 may enhance this damage by regulating NETs formation (Fig. 8).

DR is a common diabetic microvascular complication and a major cause of blindness worldwide. Currently, the main treatment options for DR include laser treatment, vitreous surgery, and intravitreal injections[33]. However, these treatments are invasive and may have side effects. Therefore, there is an urgent need to develop more effective therapeutic approaches.

Mounting evidence suggests that inflammation may cause DR. For example, results obtained from studies involving patient and animal models indicate that DR is a chronic inflammatory disease, with increased leukocyte levels playing a critical role in the initial phases of DR[11]. Neutrophils, which are the predominant leukocytes, have been implicated in the pathogenesis of DR, with elevated neutrophil levels observed in diabetic rats[34] and an increased blood neutrophil count found to be highly related to the presence and severity of both DR and DM[16]. Moreover, neutrophils participate in DR development[35], mainly by inducing vascular leakage and vascular endothelial cell damage[36]. Recently, it was found that neutrophils can release NETs, which are considered to be important in maintaining inflammation in chronic inflammatory diseases and to be associated with hyperglycemia and DR development. Menegazzo et al. reported that patients with type 2 DM had increased levels of plasma NET components compared with non-diabetic control individuals[18]. They also reported that high blood glucose levels increased NET formation both in vivo and in vitro[18]. Several other studies have shown that patients with DR have higher concentrations of NET-related molecules in the vitreous and plasma than diabetic patients without DR[19, 37, 38]. The results of our study confirm that glucose stimulation promotes NETs formation and that the amount of NETs increases with the glucose concentration, which is consistent with the findings of previous studies[19, 39]. These results suggest that NETs, which are important for maintaining the inflammatory environment, are involved in the development of not only DM but also DR.

TLRs recognize pathogen-associated molecular patterns and participate in inflammatory responses[40]. Among the TLR subtypes, TLR2 and TLR4 are closely related to the development of DM. Zhu and Devaraj et al. found that TLR2 and TLR4 expression was upregulated in the peripheral blood of diabetic patients[41, 42]. TLR4 in bone marrow-derived cells has been proven to contribute to the development of DR[43]. It has also been reported that TLR2 is involved in both the pathogenesis of type 2 DM and the development of related microvascular complications[40, 44]. Therefore, we investigated the effects of TLR2 and TLR4 on high glucose-induced NETs formation. We found that a TLR2 antagonist and a TLR4 antagonist both significantly inhibited high glucose-induced NETosis. Consistent with our observations, TLR2/TLR4 have been shown to participate in NET formation induced by T. brucei lipophosphoglycan and gut-derived lipopolysaccharide[25, 26]. Similarly, Oklu et al. reported that TLR4 mutant mice had obviously lower levels of NETs[45]. In addition, in a study with septic patients, Clark et al. demonstrated that TLR4 on platelets could activate neutrophils to release NETs and capture bacteria in the bloodstream[46]. We have also previously shown that TLRs promote the formation of NETs induced by S. aureus[27]. Together, these results indicate that TLR2/4 may modulate inflammatory reactions by regulating the formation of NETs under high glucose circumstance.

The formation of NETs can be ROS dependent or independent. In this study, an obvious oxidative burst was observed in neutrophils after high glucose stimulation. A ROS-scavenging agent (DPI) was used to verify the effect that ROS had on the observed high glucose-stimulated NETs formation, and DPI significantly inhibited the high glucose-stimulated NETs formation. These results indicated that ROS were involved in the high glucose-induced NETs formation, a finding that aligns with Wang’s results[19]. Consistent with our predictions, the TLR2 antagonist hindered the observed high glucose-induced NETs formation and reduced the ROS levels. However, the TLR4 antagonist had no significant effect. These results indicate that TLR2, but not TLR4, promotes high glucose-induced NETs formation by regulating ROS signaling. However, several other studies have reported conflicting results. Zhan et al. demonstrated that hepatitis B virus-induced S100A9 stimulates abundant NETs generation through TLR4–ROS signaling[47], and Dong et al. found that TLR4 partially mediates Streptococcus pneumonia-induced NETs generation in vitro and in vivo[48]. The discrepancy between our results and those of previous studies may be due to the use of different stimuli: we used high glucose, whereas pathogens were used in the abovementioned studies. Therefore, it is likely that the ROS signaling pathway is involved in TLR2-regulated high glucose-induced NETs formation but not in TLR4-regulated high glucose-induced NETs formation. These findings indicate that there are other important signaling pathways involved in TLR4-mediated high glucose-induced NETs formation that must be elucidated.

Neutrophils are the major cells responsible for the disruption of vascular barrier function, and increased neutrophil–endothelial cell adhesion has been proved to contribute to the progression of DR[49]^,[50]. As a newly discovered neutrophil action form, NETs were initially found to be critical for pathogen clearance. However, a growing number of studies have shown that an excessive amount of NETs is deleterious to the function vascular endothelial cells[51–53], possibly by upregulating adhesion molecule expression. To investigate the role that neutrophils play in the function of the vascular endothelium under high-glucose conditions and the underlying mechanisms, we explored not only the effect of high glucose on neutrophil–HUVEC adhesion but also the influence that HGNs have on HUVEC proliferation, migration, and permeability. We utilized DNase I to degrade NETs and cytochalasin D to inhibit neutrophil phagocytosis so that the effects of NETs and neutrophil phagocytosis could be distinguished. We found that HGNs enhanced neutrophil–HUVEC adhesion, inhibited the migration of endothelial cells, and increased the permeability of the endothelial cell barrier, which could be alleviated by DNase I but not cytochalasin D. These results indicate that HGNs mainly interact with endothelial cells via NETs formation and not phagocytosis. Consistent with our results, Desilles et al.[54] and Omi et al.[55] demonstrated that high glucose levels increased neutrophil–endothelial cell adhesion. Moreover, Gupta et al.[56] found that in a high-glucose environment, NETs damage the glomerular endothelial filtration barrier.

Previously, we found that alkali-activated neutrophils promote human corneal epithelial cell proliferation via phagocytosis[57]. Similarly, in this study, we found that glucose-activated neutrophils promote endothelial cell proliferation, which was inhibited by cytochalasin D but not DNase I. However, the proliferative effect induced by HGNs only occurs when HUVECs are at low concentrations. When HUVECs are at high concentrations, HGNs do not significantly promote their proliferation. We speculate that this may be due to contact inhibition at higher cell densities, which slows down cell proliferation.These findings suggest that glucose-activated neutrophils promote HUVEC proliferation via phagocytosis and not NETs. We speculate that HGNs clear damaged cells and toxins from the microenvironment to maintain the health and proliferation of endothelial cells. Contrary to our results, Aldabbous et al.[58] found that phorbol-12-myristate-13-acetate induced NETs promoted endothelial proliferation. Our results may differ from those of Aldabbous due to differences in the stimuli used. Furthermore, Qiu et al.[59] found that high glucose reduced tumor necrosis factor-a-induced endothelial cell proliferation in vitro, which may lead to delayed wound repair in patients with DM. The discrepancy between our results and the abovementioned results may have been due to the fact that Qiu used TNF-a and glucose, whereas we used HGNs in this study. Nevertheless, our results indicate that HGNs may exert different effects through different pathways; specifically, they may promote endothelial cell proliferation through phagocytosis, while also enhance neutrophil–HUVEC adhesion, inhibit endothelial cell migration, and damage the endothelial barrier function by generating NETs. This may explain why patients with DR can experience inflammation-related angiogenesis as well as vascular leakage and related vision issues due to poor endothelial barrier function.

It is known that TLR2 and TLR4 are positively associated with the development of type 2 DM, as hyperglycemia leads to TLR2 upregulation, and insulin inhibits TLR2 expression[60, 61]. It has also been shown that inhibiting TLR4 prevents autoimmune DM in non-obese diabetic mice[62]. Furthermore, TLR2 and TLR4 have been implicated in the pathogenesis of diabetic vascular complications, including DR[40]. Fu et al. observed that the DR present in diabetic TLR4-/- mice was less severe than that in diabetic wild type mice[31], and Bayan et al. reported that hyperglycemia contributed to the pathogenesis of DR by promoting TLR4 expression[28]. Moreover, deletion of TLR2/4 has been shown to inhibit not only leukostasis but also endothelial death induced by DM[63]. In the present study, TLR2 and TLR4 were found to be involved in high glucose-induced endothelial cell dysfunction, because both a TLR2 antagonist and a TLR4 antagonist could inhibit HGN-induced neutrophil–HUVEC adhesion, reduction in HUVEC migration, and endothelial barrier function damage. Thus, we postulated that the TLR2 and TLR4 antagonists modulated the HGN-induced endothelial cell dysfunction by regulating NETs formation. Consequently, the use of TLR2 and TLR4 antagonists may be a new strategy for preventing hyperglycemia-induced vascular endothelial cell dysfunction.

In summary, our results indicate that high glucose can cause an oxidative burst in neutrophils and subsequent NETosis. TLR2 antagonists may inhibit high glucose-induced NETs formation through an ROS-dependent pathway. Furthermore, high glucose-activated neutrophils enhance HUVEC proliferation through phagocytosis, and lead to HUVEC-neutrophil adhesion, HUVEC migration inhibition and HUVEC barrier destruction by generating NETs. Given that TLR2 and TLR4 antagonists may alleviate HGN-induced damage to HUVECs, their use should be investigated as a strategy for delaying the development of DR.

Ethics approval:

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (protocol code 20210011; 2 January 2021).” for studies involving humans.

Consent to participate:

Informed consent was obtained from all individual participants included in the study.

Competing Interests:

The authors have no relevant financial or non-financial interests to disclose..

Funding information:

This research was funded by National Natural Science Foundation of China (No. 81870558); Zhejiang Provincial Natural Science Foundation of China (No.LGC20H120001, LY20H120010)

Author Contribution

Material preparation was performed by Shirou Wu, Yahui Chen. The data collection was performed by Shirou Wu, Yahui Chen, Xiuming Jin, Jiayun Yu, Xueping Chen and Ting Wan.The data analysis was performed by Shirou Wu, Yahui Chen and Ting Wan. The first draft of the manuscript was written by Shirou Wu. The final draft of the manuscript was written by Shirou Wu and Ting Wan and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgement:

We would like to thank the participants in this study.

Data Availability

Data is provided within the manuscript or supplementary information files.

Zimmet, Paul Z, Dianna J Magliano, William H Herman, and Jonathan E Shaw. 2014. Diabetes: a 21st century challenge. The Lancet Diabetes & Endocrinology 2: 56–64. https://doi.org/10.1016/S2213-8587(13)70112-8.
Saeedi, Pouya, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, et al. 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice 157: 107843. https://doi.org/10.1016/j.diabres.2019.107843.
Kobrin Klein, Barbara Eden. 2007. Overview of Epidemiologic Studies of Diabetic Retinopathy. Ophthalmic Epidemiology 14: 179–183. https://doi.org/10.1080/09286580701396720.
Kempen, John H., Benita J. O’Colmain, M. Cristina Leske, Steven M. Haffner, Ronald Klein, Scot E. Moss, Hugh R. Taylor, Richard F. Hamman, and Eye Diseases Prevalence Research Group. 2004. The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology (Chicago, Ill.: 1960) 122: 552–563. https://doi.org/10.1001/archopht.122.4.552.
Yau, Joanne W.Y., Sophie L. Rogers, Ryo Kawasaki, Ecosse L. Lamoureux, Jonathan W. Kowalski, Toke Bek, Shih-Jen Chen, et al. 2012. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care 35: 556–564. https://doi.org/10.2337/dc11-1909.
Ellis, Michael Patrick, Daniella Lent-Schochet, Therlinder Lo, and Glenn Yiu. 2019. Emerging Concepts in the Treatment of Diabetic Retinopathy. Current Diabetes Reports 19: 137. https://doi.org/10.1007/s11892-019-1276-5.
Antoszyk, Andrew N., Adam R. Glassman, Wesley T. Beaulieu, Lee M. Jampol, Chirag D. Jhaveri, Omar S. Punjabi, Hani Salehi-Had, et al. 2020. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 324: 2383. https://doi.org/10.1001/jama.2020.23027.
Jones, Relief, and Douglas J. Rhee. 2006. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Current Opinion in Ophthalmology 17: 163–167. https://doi.org/10.1097/01.icu.0000193079.55240.18.
Niu, Yifei, Junfeng Ji, Ke Yao, and Qiuli Fu. 2024. Regenerative treatment of ophthalmic diseases with stem cells: Principles, progress, and challenges. Advances in Ophthalmology Practice and Research 4: 52–64. https://doi.org/10.1016/j.aopr.2024.02.001.
Chen, Zhiqing, Binbin Chen, Peike Hu, Haipeng Liu, and Dingchang Zheng. 2022. A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema. Advances in Ophthalmology Practice and Research 2: 100051. https://doi.org/10.1016/j.aopr.2022.100051.
Yue, Tong, Yu Shi, Sihui Luo, Jianping Weng, Yali Wu, and Xueying Zheng. 2022. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Frontiers in Immunology 13: 1055087. https://doi.org/10.3389/fimmu.2022.1055087.
Lin, Wen-jian, and Hong-yu Kuang. 2014. Oxidative stress induces autophagy in response to multiple noxious stimuli in retinal ganglion cells. Autophagy 10: 1692–1701. https://doi.org/10.4161/auto.36076.
Klaassen, Ingeborg, Cornelis J.F. Van Noorden, and Reinier O. Schlingemann. 2013. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Progress in Retinal and Eye Research 34: 19–48. https://doi.org/10.1016/j.preteyeres.2013.02.001.
Forrester, John V., Lucia Kuffova, and Mirela Delibegovic. 2020. The Role of Inflammation in Diabetic Retinopathy. Frontiers in Immunology 11: 583687. https://doi.org/10.3389/fimmu.2020.583687.
Tang, Johnny, and Timothy S. Kern. 2011. Inflammation in diabetic retinopathy. Progress in Retinal and Eye Research 30: 343–358. https://doi.org/10.1016/j.preteyeres.2011.05.002.
Woo, Se Joon, Seong Joon Ahn, Jeeyun Ahn, Kyu Hyung Park, and Kiheon Lee. 2011. Elevated systemic neutrophil count in diabetic retinopathy and diabetes: a hospital-based cross-sectional study of 30,793 Korean subjects. Investigative Ophthalmology & Visual Science 52: 7697–7703. https://doi.org/10.1167/iovs.11-7784.
Brinkmann, Volker, Ulrike Reichard, Christian Goosmann, Beatrix Fauler, Yvonne Uhlemann, David S. Weiss, Yvette Weinrauch, and Arturo Zychlinsky. 2004. Neutrophil Extracellular Traps Kill Bacteria. Science 303: 1532–1535. https://doi.org/10.1126/science.1092385.
Menegazzo, Lisa, Stefano Ciciliot, Nicol Poncina, Marta Mazzucato, Mariasara Persano, Benedetta Bonora, Mattia Albiero, Saula Vigili De Kreutzenberg, Angelo Avogaro, and Gian Paolo Fadini. 2015. NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetologica 52: 497–503. https://doi.org/10.1007/s00592-014-0676-x.
Wang, Luoziyi, Xin Zhou, Yizhou Yin, Yuxin Mai, Desai Wang, and Xuedong Zhang. 2019. Hyperglycemia Induces Neutrophil Extracellular Traps Formation Through an NADPH Oxidase-Dependent Pathway in Diabetic Retinopathy. Frontiers in Immunology 9: 3076. https://doi.org/10.3389/fimmu.2018.03076.
Safi, Rémi, Romy Kallas, Tara Bardawil, Carl Joe Mehanna, Ossama Abbas, Rola Hamam, Imad Uthman, Abdul-Ghani Kibbi, and Dany Nassar. 2018. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet’s disease. Journal of Dermatological Science 92: 143–150. https://doi.org/10.1016/j.jdermsci.2018.08.010.
Qi, Haozhe, Shuofei Yang, and Lan Zhang. 2017. Neutrophil Extracellular Traps and Endothelial Dysfunction in Atherosclerosis and Thrombosis. Frontiers in Immunology 8: 928. https://doi.org/10.3389/fimmu.2017.00928.
Wang, Heng, Tingting Gao, Ruijing Zhang, Jie Hu, Siqi Gao, Yuwen Wang, Xiaotong Qi, Yun Zhou, Guoping Zheng, and Honglin Dong. 2023. Neutrophil Extracellular Traps Aggravate Contrast-Induced Acute Kidney Injury by Damaging Glomeruli and Peritubular Capillaries. Journal of Inflammation Research 16: 5629–5646. https://doi.org/10.2147/JIR.S433110.
Takeda, Kiyoshi, Tsuneyasu Kaisho, and Shizuo Akira. 2003. Toll-Like Receptors. Annual Review of Immunology 21: 335–376. https://doi.org/10.1146/annurev.immunol.21.120601.141126.
Roeder, Alexander, Carsten J. Kirschning, Rudolf A. Rupec, Martin Schaller, Günther Weindl, and Hans Christian Korting. 2004. Toll-like receptors as key mediators in innate antifungal immunity. Medical Mycology 42: 485–498. https://doi.org/10.1080/13693780400011112.
Zhang, Kai, Ning Jiang, Xiaoyu Sang, Ying Feng, Ran Chen, and Qijun Chen. 2021. Trypanosoma brucei Lipophosphoglycan Induces the Formation of Neutrophil Extracellular Traps and Reactive Oxygen Species Burst via Toll-Like Receptor 2, Toll-Like Receptor 4, and c-Jun N-Terminal Kinase Activation. Frontiers in Microbiology 12: 713531. https://doi.org/10.3389/fmicb.2021.713531.
Liu, Yang, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, et al. 2022. Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4. Clinical and Molecular Hepatology 28: 522–539. https://doi.org/10.3350/cmh.2022.0039.
Wan, Ting, Yingying Zhao, Fangli Fan, Renjian Hu, and Xiuming Jin. 2017. Dexamethasone Inhibits S. aureus-Induced Neutrophil Extracellular Pathogen-Killing Mechanism, Possibly through Toll-Like Receptor Regulation. Frontiers in Immunology 8. https://doi.org/10.3389/fimmu.2017.00060.
Bayan, Nikoo, Niloufar Yazdanpanah, and Nima Rezaei. 2022. Role of toll-like receptor 4 in diabetic retinopathy. Pharmacological Research 175: 105960. https://doi.org/10.1016/j.phrs.2021.105960.
Zhu, T, Q Meng, J Ji, L Zhang, and X Lou. 2017. TLR4 and Caveolin‐1 in Monocytes Are Associated With Inflammatory Conditions in Diabetic Neuropathy. Clinical and Translational Science 10: 178–184. https://doi.org/10.1111/cts.12434.
Kim, Hun Sik, Myoung Sook Han, Kun Wook Chung, Sunshin Kim, Eunshil Kim, Myoung Joo Kim, Eunkyeong Jang, et al. 2007. Toll-like Receptor 2 Senses β-Cell Death and Contributes to the Initiation of Autoimmune Diabetes. Immunity 27: 321–333. https://doi.org/10.1016/j.immuni.2007.06.010.
Fu, Hongyu, and Huiqiang Liu. 2023. Deletion of toll-like receptor 4 ameliorates diabetic retinopathy in mice. Archives of Physiology and Biochemistry 129: 519–525. https://doi.org/10.1080/13813455.2020.1841795.
Zhang, Yuqi, Huanhuan Li, Chenyi Wang, Haihong Lv, and Songbo Fu. 2022. Toll like receptor 4 gene Asp299Gly polymorphism increases the risk of diabetic microvascular complications: a meta analysis. Diabetology & Metabolic Syndrome 14: 79. https://doi.org/10.1186/s13098-022-00849-2.
Mitchell, Paul, and Tien Yin Wong. 2014. Management Paradigms for Diabetic Macular Edema. American Journal of Ophthalmology 157: 505-513.e8. https://doi.org/10.1016/j.ajo.2013.11.012.
Nabi, A.H.M. Nurun, Laila N. Islam, Mohanmmad Mahfuzur Rahman, and Kazal Boron Biswas. 2005. Polymorphonuclear Neutrophil Dysfunctions in Streptozotocin-induced Type 1 Diabetic Rats. BMB Reports 38: 661–667. https://doi.org/10.5483/BMBRep.2005.38.6.661.
Shafqat, Areez, Saleha Abdul Rab, Osama Ammar, Sulaiman Al Salameh, Anas Alkhudairi, Junaid Kashir, Khaled Alkattan, and Ahmed Yaqinuddin. 2022. Emerging role of neutrophil extracellular traps in the complications of diabetes mellitus. Frontiers in Medicine 9: 995993. https://doi.org/10.3389/fmed.2022.995993.
Liu, Haitao, Emma M. Lessieur, Aicha Saadane, Sarah I. Lindstrom, Patricia R. Taylor, and Timothy S. Kern. 2019. Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy. Diabetologia 62: 2365–2374. https://doi.org/10.1007/s00125-019-04998-4.
Park, J.-H., J.-E. Kim, J.-Y. Gu, H. Yoo, S. Park, Y. Kim, I. Nam-Goong, E. Kim, and H. Kim. 2016. Evaluation of Circulating Markers of Neutrophil Extracellular Trap (NET) Formation as Risk Factors for Diabetic Retinopathy in a Case-Control Association Study. Experimental and Clinical Endocrinology & Diabetes 124: 557–561. https://doi.org/10.1055/s-0042-101792.
Martínez-Alberquilla, Irene, Xavier Gasull, Patricia Pérez-Luna, Rubén Seco-Mera, Javier Ruiz-Alcocer, and Almudena Crooke. 2022. Neutrophils and neutrophil extracellular trap components: Emerging biomarkers and therapeutic targets for age-related eye diseases. Ageing Research Reviews 74: 101553. https://doi.org/10.1016/j.arr.2021.101553.
Wong, Siu Ling, Melanie Demers, Kimberly Martinod, Maureen Gallant, Yanming Wang, Allison B. Goldfine, C. Ronald Kahn, and Denisa D. Wagner. 2015. Diabetes primes neutrophils to undergo NETosis which severely impairs wound healing. Nature medicine 21: 815–819. https://doi.org/10.1038/nm.3887.
Jialal, Ishwarlal, and Harmeet Kaur. 2012. The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications. Current Diabetes Reports 12: 172–179. https://doi.org/10.1007/s11892-012-0258-7.
Zhu, Tao, Qingsheng Meng, Jian Ji, Xiaoli Lou, and Lijuan Zhang. 2015. Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neuroscience Letters 585: 28–32. https://doi.org/10.1016/j.neulet.2014.11.020.
Devaraj, Sridevi, Mohan R. Dasu, Jason Rockwood, William Winter, Steven C. Griffen, and Ishwarlal Jialal. 2008. Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State. The Journal of Clinical Endocrinology & Metabolism 93: 578–583. https://doi.org/10.1210/jc.2007-2185.
Wang, Hui, Haojun Shi, Jing Zhang, Guoliang Wang, Jinxiang Zhang, Fagang Jiang, and Qing Xiao. 2014. Toll-like receptor 4 in bone marrow-derived cells contributes to the progression of diabetic retinopathy. Mediators of Inflammation 2014: 858763. https://doi.org/10.1155/2014/858763.
Sepehri, Zahra, Zohre Kiani, Ali Akbar Nasiri, and Farhad Kohan. 2016. Toll-like receptor 2 and type 2 diabetes. Cellular & Molecular Biology Letters 21: 2. https://doi.org/10.1186/s11658-016-0002-4.
Oklu, Rahmi, Hassan Albadawi, John E. Jones, Hyung-Jin Yoo, and Michael T. Watkins. 2013. Reduced hind limb ischemia-reperfusion injury in Toll-like receptor-4 mutant mice is associated with decreased neutrophil extracellular traps. Journal of Vascular Surgery 58: 1627–1636. https://doi.org/10.1016/j.jvs.2013.02.241.
Clark, Stephen R, Adrienne C Ma, Samantha A Tavener, Braedon McDonald, Zahra Goodarzi, Margaret M Kelly, Kamala D Patel, et al. 2007. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Medicine 13: 463–469. https://doi.org/10.1038/nm1565.
Zhan, Xi, Rui Wu, Xue-Hua Kong, Yan You, Yong Huang, Wei-Xian Chen, Liang Duan, Kun He, and Xiao-Yu Sun. Elevated neutrophil extracellular traps by HBV‐mediated S100A9‐TLR4/RAGE‐ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma.
Dong, Yilin, Chunfang Jin, Zhiqiang Ding, Yiting Zhu, Qian He, Xinxin Zhang, Rongshuang Ai, Yibing Yin, and Yujuan He. 2021. TLR4 regulates ROS and autophagy to control neutrophil extracellular traps formation against Streptococcus pneumoniae in acute otitis media. Pediatric Research 89: 785–794. https://doi.org/10.1038/s41390-020-0964-9.
Ma, Yonggang, Xiaoyuan Yang, Victor Chatterjee, Jamie E. Meegan, Richard S. Beard, and Sarah Y. Yuan. 2019. Role of Neutrophil Extracellular Traps and Vesicles in Regulating Vascular Endothelial Permeability. Frontiers in Immunology 10: 1037. https://doi.org/10.3389/fimmu.2019.01037.
Barouch, F. C., K. Miyamoto, J. R. Allport, K. Fujita, S. E. Bursell, L. P. Aiello, F. W. Luscinskas, and A. P. Adamis. 2000. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Investigative Ophthalmology & Visual Science 41: 1153–1158.
Lu, Yuan, Yan Dong, Yan Zhang, Di Shen, Xiyao Wang, Ruxiu Ge, Meihua Zhang, Yu Xia, and Xietong Wang. 2020. Antiphospholipid antibody‐activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome. Journal of Cellular and Molecular Medicine 24: 6690–6703. https://doi.org/10.1111/jcmm.15321.
Zhao, Peipei, Jiarui Zhu, Ling Bai, Wenlan Ma, Feifei Li, Cen Zhang, Liangtao Zhao, Liuyang Wang, and Sigong Zhang. 2024. Neutrophil extracellular traps induce pyroptosis of pulmonary microvascular endothelial cells by activating the NLRP3 inflammasome. Clinical and Experimental Immunology: uxae028. https://doi.org/10.1093/cei/uxae028.
Zhu, Shuainan, Ying Yu, Qianya Hong, Chenning Li, Hao Zhang, and Kefang Guo. 2024. Neutrophil Extracellular Traps Upregulate p21 and Suppress Cell Cycle Progression to Impair Endothelial Regeneration after Inflammatory Lung Injury. Journal of Clinical Medicine 13: 1204. https://doi.org/10.3390/jcm13051204.
Desilles, Jean-Philippe, Varouna Syvannarath, Véronique Ollivier, Clément Journé, Sandrine Delbosc, Célina Ducroux, William Boisseau, et al. 2017. Exacerbation of Thromboinflammation by Hyperglycemia Precipitates Cerebral Infarct Growth and Hemorrhagic Transformation. Stroke 48: 1932–1940. https://doi.org/10.1161/STROKEAHA.117.017080.
Omi, Hitoshi, Naotsuka Okayama, Manabu Shimizu, Masahiro Okouchi, Shigenori Ito, Tatsuya Fukutomi, and Makoto Itoh. 2002. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells Effect of antidiabetic medicines. Journal of Diabetes and Its Complications.
Gupta, Anubhuti, Kunal Singh, Sameen Fatima, Saira Ambreen, Silke Zimmermann, Ruaa Younis, Shruthi Krishnan, et al. 2022. Neutrophil Extracellular Traps Promote NLRP3 Inflammasome Activation and Glomerular Endothelial Dysfunction in Diabetic Kidney Disease. Nutrients 14: 2965. https://doi.org/10.3390/nu14142965.
Wan, Ting, Yue Zhang, Kelan Yuan, Jinjin Min, Yujie Mou, and Xiuming Jin. 2020. Acetylsalicylic Acid Promotes Corneal Epithelium Migration by Regulating Neutrophil Extracellular Traps in Alkali Burn. Frontiers in Immunology 11: 551057. https://doi.org/10.3389/fimmu.2020.551057.
Aldabbous, Lulwah, Vahitha Abdul-Salam, Tom McKinnon, Lucie Duluc, Joanna Pepke-Zaba, Mark Southwood, Alexander J. Ainscough, et al. 2016. Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology 36: 2078–2087. https://doi.org/10.1161/ATVBAHA.116.307634.
Qiu, Dongxu, Lei Zhang, Junkun Zhan, Qiong Yang, Hongliang Xiong, Weitong Hu, Qiao Ji, and Jiabing Huang. 2020. Hyperglycemia Decreases Epithelial Cell Proliferation and Attenuates Neutrophil Activity by Reducing ICAM-1 and LFA-1 Expression Levels. Frontiers in Genetics 11: 616988. https://doi.org/10.3389/fgene.2020.616988.
Ahmad, Rasheed, Anfal Al-Mass, Valerie Atizado, Asma Al-Hubail, Fahad Al-Ghimlas, Monira Al-Arouj, Abdullah Bennakhi, Said Dermime, and Kazem Behbehani. 2012. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. Journal of Inflammation (London, England) 9: 48. https://doi.org/10.1186/1476-9255-9-48.
Promsudthi, A., S. Poomsawat, and W. Limsricharoen. 2014. The role of Toll-like receptor 2 and 4 in gingival tissues of chronic periodontitis subjects with type 2 diabetes. Journal of Periodontal Research 49: 346–354. https://doi.org/10.1111/jre.12112.
Alibashe-Ahmed, Mohamed, Estelle Brioudes, Walter Reith, Domenico Bosco, and Thierry Berney. 2019. Toll-like receptor 4 inhibition prevents autoimmune diabetes in NOD mice. Scientific Reports 9: 19350. https://doi.org/10.1038/s41598-019-55521-z.
Tang, Jie, Chieh Allen Lee, Yunpeng Du, Yan Sun, Eric Pearlman, Nader Sheibani, and Timothy S. Kern. 2013. MyD88-dependent pathways in leukocytes affect the retina in diabetes. PloS One 8: e68871. https://doi.org/10.1371/journal.pone.0068871.

No competing interests reported.

Download PDF

Editorial decision: Revision requested
18 Oct, 2024
Reviews received at journal
26 Sep, 2024
Reviews received at journal
22 Sep, 2024
Reviewers agreed at journal
14 Sep, 2024
Reviewers agreed at journal
12 Sep, 2024
Reviewers agreed at journal
12 Sep, 2024
Reviewers agreed at journal
11 Sep, 2024
Reviewers invited by journal
11 Sep, 2024
Editor assigned by journal
09 Sep, 2024
Submission checks completed at journal
09 Sep, 2024
First submitted to journal
07 Sep, 2024

You are reading this latest preprint version

Toll like receptors promote high glucose-induced vascular endothelial cell dysfunction by regulating neutrophil extracellular traps formation

Status:

Version 1

Abstract

Figures

1. Introduction

2. Materials and Methods

2.1. Reagents

2.2. Human Primary Neutrophils Isolation

2.3. Neutrophils Stimulation

2.4. Immunofluorescence for NETs Formation

2.5. ROS Production

2.6. HUVEC stimulation

2.7. HUVEC Proliferation Assessment

2.8. Neutrophil-HUVEC Adhesion Assay

2.9. HUVEC Migration Assay

2.10. HUVEC Permeability Assay

2.11. Statistical Analysis

3. Results

3.1. High glucose level promoted NETs formation

3.2. High glucose-induced NETs formation was inhibited by a TLR2 antagonist and a TLR4 antagonist

3.3. ROS production was involved in TLR2- but not TLR4-regulated NETs formation

3.4. HGNs promoted HUVEC proliferation via phagocytosis and not via NETs

3.5. NETs were involved in high glucose-induced neutrophil–HUVEC adhesion, which could be inhibited by a TLR2 antagonist and a TLR4 antagonist

3.6. HGNs inhibited HUVEC migration by generating NETs, and the migration could be partially rescued by a TLR2 antagonist and a TLR4 antagonist

3.7. HGNs disrupted the barrier function of HUVECs through NETs formation, and TLRs may have modulated this process

4. Discussion

Declarations

Ethics approval:

Competing Interests:

Funding information:

Author Contribution

Acknowledgement:

Data Availability

References

Additional Declarations

Status:

Version 1